Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing director of Prescient Therapeutics (ASX:PTX).

Prescient is focused on developing novel, personalised therapies against a range of cancers.

The company’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.

Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, and spanning a range of different cancers.

The company made headlines earlier this month with news of its partnership with global cancer heavyweight Peter MacCallum Cancer Centre to develop new treatments.

Click below to hear more.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

The post Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *